Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

(2009) V. Perez-Andreu et al.   BLOOD

Pharmacoepigenetics: Its Role in Interindividual Differences in Drug Response

(2009) A Gomez et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant

(2009) M. G. McDonald et al.   MOLECULAR PHARMACOLOGY

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

(2009) Fumihiko Takeuchi et al.   PLoS Genetics

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy

(2008) C. Li et al.   BLOOD

CYP4F2 genetic variant alters required warfarin dose

(2008) M. D. Caldwell et al.   BLOOD

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

(2008) G. M. Cooper et al.   BLOOD

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans

(2008) H Schelleman et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic Determinants of Response to Warfarin during Initial Anticoagulation

(2008) Ute I. Schwarz et al.   NEW ENGLAND JOURNAL OF MEDICINE